文献速递呼吸道感染呼吸危重症与机械通气

辛伐他汀改善肺炎患者中性粒细胞功能与临床结局:一项初步随机对照临床试验

Simvastatin Improves Neutrophil Function and Clinical Outcomes in Pneumonia. A Pilot Randomized Controlled Clinical Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2019-01-01

这项随机双盲安慰剂对照先导研究纳入55岁及以上因社区获得性肺炎伴脓毒症(CAP+S)住院、未入重症监护的患者,给予辛伐他汀80 mg或安慰剂7天。第4天主要终点为中性粒细胞胞外诱捕网形成(NETosis)变化;结果显示辛伐他汀改善NETosis和趋化性、降低中性粒细胞弹性蛋白酶负荷并改善SOFA评分,事后分析提示无住院生存改善,药物耐受良好。

要点

  • 辛伐他汀80 mg用7天可改善老年CAP+S患者中性粒细胞NETosis和趋化性。
  • 辛伐他汀降低系统性中性粒细胞弹性蛋白酶负荷并改善SOFA评分。
  • 事后分析提示辛伐他汀与无住院生存改善相关,但需多中心确证。

核心结论

  • 该先导研究支持高剂量辛伐他汀作为老年、病情较既往研究更轻的CAP+S患者的辅助治疗。
  • 仍需确定性多中心研究评估该人群的获益与 harm 可能性。

研究设计与样本

  • 随机、双盲、安慰剂对照先导研究,辛伐他汀80 mg或安慰剂治疗7天。
  • 对象为55岁及以上、因社区获得性肺炎伴脓毒症住院且未入重症监护的患者,收治于二级医院。
  • 第4天主要终点为中性粒细胞胞外诱捕网形成(NETosis)变化。

主要发现

  • 与安慰剂相比,辛伐他汀辅助治疗4天与系统性中性粒细胞功能(NETosis和趋化性)改善相关。
  • 与安慰剂相比,辛伐他汀辅助治疗4天与系统性中性粒细胞弹性蛋白酶负荷降低相关。
  • 与安慰剂相比,辛伐他汀辅助治疗4天与序贯器官衰竭评估(SOFA)评分改善相关。
  • 事后分析显示辛伐他汀治疗与无住院生存改善相关。
  • 辛伐他汀在老年多病共存且常联合使用大环内酯类抗生素的患者组中耐受良好。

关键数值与推荐

  • 辛伐他汀剂量为80 mg,疗程7天。
  • 第4天主要终点为中性粒细胞胞外诱捕网形成(NETosis)变化。
  • 第4天次要终点包括中性粒细胞趋化性、安全性与耐受性、SOFA评分、死亡率、再入院及组织降解/炎症标志物。

临床怎么用

  • 对55岁及以上、CAP+S住院但未入重症监护的患者,可考虑高剂量辛伐他汀作为辅助治疗。
  • 该先导研究提示辛伐他汀在此人群耐受良好,可与大环内酯类抗生素联用。
  • 临床获益尚需确定性多中心研究验证,暂不宜据此常规改变实践。

局限性

  • 为先导性单中心研究,样本量有限。
  • 无住院生存改善为事后分析结果,需谨慎解读。
  • 研究人群为病情较既往研究更轻的老年患者,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Population studies suggest improved sepsis outcomes with statins, but the results of randomized controlled trials in patients with sepsis and organ dysfunction in critical care settings have broadly been negative. In vitro data suggest that statins modulate age-related neutrophil functions, improving neutrophil responses to infection, but only in older patients and at high doses.Objectives: To determine if high-dose simvastatin improves neutrophil functions and is safe and tolerated in hospitalized older adults with community-acquired pneumonia with sepsis (CAP + S) not admitted to critical care.Methods: We conducted a randomized, double-blind, placebo-controlled pilot study of simvastatin 80 mg or placebo for 7 days for patients with CAP + S aged 55 years or older admitted to a secondary care hospital. The Day 4 primary endpoint was change in neutrophil extracellular trap formation (NETosis). Day 4 secondary endpoints included neutrophil chemotaxis, safety and tolerability, Sequential Organ Failure Assessment score, mortality, readmission, and markers of tissue degradation/inflammation.Measurements and Main Results: Four days of simvastatin adjuvant therapy in patients with CAP + S was associated with improvements in systemic neutrophil function (NETosis and chemotaxis), a reduction in systemic neutrophil elastase burden, and improved Sequential Organ Failure Assessment scores compared with placebo. A post hoc analysis demonstrated that simvastatin therapy was associated with improved hospitalization-free survival compared with placebo. Simvastatin was well tolerated in this elderly and multimorbid patient group with common coprescription of macrolide antibiotics.Conclusions: This pilot study supports high-dose simvastatin as an adjuvant therapy for CAP + S in an older and milder disease cohort than assessed previously. A definitive multicenter study is now warranted in this population to assess the likelihood of benefit and harm.Clinical trial registered with EudraCT (2012-00343-29).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Sapey E, Patel JM, Greenwood H, et al. Simvastatin Improves Neutrophil Function and Clinical Outcomes in Pneumonia. A Pilot Randomized Controlled Clinical Trial. Am J Respir Crit Care Med. 2019. PMID: 31206313. doi:10.1164/rccm.201812-2328OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。